GlassScriptPhysician profile
Marc Robert Labbe
NPI 1306889886
$237,701.45
in general payments reported to CMS, 2019-2025
15 companies · $18K in 2025
The $18K reported for 2025 was more than what 90% of Sports Medicine (Orthopaedic Surgery) providers received nationally (typical 2025 total: $686).
See the full distribution for Sports Medicine (Orthopaedic Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73K · 2020: $30K · 2021: $29K · 2022: $23K · 2023: $15K · 2024: $51K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $63K · Travel and Lodging: $13K · Food and Beverage: $3,947 · Royalty Or License: $2,387 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $62,998.17 |
| Travel and Lodging | $12,508.61 |
| Food and Beverage | $3,947.26 |
| Royalty Or License | $2,386.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $113,562.83 | 2019-2025 | Inhance, Mitek, Dynacord |
| Smith+Nephew, INC. | $65,609.17 | 2019-2023 | Bioinductive Implant With Arthroscopic Delivery System - Medium, Healicoil, Stravix Pl |
| Depuy Synthes Products, INC. | $43,432.09 | 2019-2024 | Fms |
| Integrity Orthopaedics, INC. | $11,713.48 | 2024-2025 | Integrity Orthopaedics |
| Briohealth Solutions, INC. | $2,100.00 | 2025 | Briovad |
| Depuy Synthes Sales INC. | $811.40 | 2019-2025 | Healix Knotless Peek, Orthovisc, Monovisc |
| Bioventus LLC | $155.69 | 2023-2025 | Durolane, Durolane, Xcell |
| Becton, Dickinson and Company | $89.39 | 2024 | Channel Drain |
| Fx Shoulder Solutions, INC | $81.11 | 2022 | |
| Pacira Therapeutics, INC. | $57.02 | 2020 | |
| Davol INC. | $20.88 | 2025 | Channel Drain |
| Vericel Corporation | $18.92 | 2024 | Maci |
| Ferring Pharmaceuticals INC. | $17.54 | 2022 | |
| Catalyst Orthoscience | $17.47 | 2021 | |
| Xiros INC | $14.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,225,296.78 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Labbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.